Leerink Partnrs Issues Optimistic Forecast for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for shares of Hims & Hers Health in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.15 per share for the quarter, up from their previous estimate of $0.13. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q3 2025 earnings at $0.17 EPS, FY2025 earnings at $0.69 EPS, FY2026 earnings at $0.79 EPS and FY2027 earnings at $1.20 EPS.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter last year, the company earned $0.05 EPS.

Several other brokerages have also recently weighed in on HIMS. Needham & Company LLC reiterated a “buy” rating and set a $61.00 price target on shares of Hims & Hers Health in a research note on Tuesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday. UBS Group reissued a “mixed” rating on shares of Hims & Hers Health in a research note on Tuesday. Truist Financial decreased their target price on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a research report on Thursday, April 10th. Finally, Citigroup reiterated a “sell” rating and issued a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $37.67.

Hims & Hers Health Stock Down 1.8 %

Shares of NYSE HIMS opened at $51.43 on Wednesday. The company has a market cap of $11.43 billion, a PE ratio of 116.89 and a beta of 1.84. The firm’s 50-day moving average price is $32.74 and its 200-day moving average price is $32.16. Hims & Hers Health has a 52-week low of $12.07 and a 52-week high of $72.98.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC increased its stake in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC raised its position in Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after acquiring an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company’s stock valued at $104,724,000 after buying an additional 40,447 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 33,333 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the sale, the chief operating officer now owns 805,083 shares in the company, valued at approximately $20,755,039.74. This represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 650,500 shares of company stock valued at $25,790,311. 17.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.